Human Investing LLC Buys New Position in STERIS plc (NYSE:STE)

Human Investing LLC purchased a new position in shares of STERIS plc (NYSE:STEFree Report) during the fourth quarter, Holdings Channel.com reports. The fund purchased 152 shares of the medical equipment provider’s stock, valued at approximately $31,000.

Several other hedge funds have also made changes to their positions in STE. Magnolia Capital Advisors LLC increased its stake in STERIS by 1.9% during the 4th quarter. Magnolia Capital Advisors LLC now owns 2,534 shares of the medical equipment provider’s stock worth $521,000 after buying an additional 48 shares during the period. SkyView Investment Advisors LLC grew its stake in shares of STERIS by 1.6% in the third quarter. SkyView Investment Advisors LLC now owns 3,153 shares of the medical equipment provider’s stock worth $765,000 after acquiring an additional 51 shares in the last quarter. Park Edge Advisors LLC increased its position in shares of STERIS by 1.1% during the fourth quarter. Park Edge Advisors LLC now owns 4,662 shares of the medical equipment provider’s stock worth $958,000 after acquiring an additional 51 shares during the period. Opal Wealth Advisors LLC raised its stake in shares of STERIS by 5.7% in the fourth quarter. Opal Wealth Advisors LLC now owns 1,118 shares of the medical equipment provider’s stock valued at $230,000 after acquiring an additional 60 shares in the last quarter. Finally, Sage Private Wealth Group LLC boosted its holdings in STERIS by 4.1% in the fourth quarter. Sage Private Wealth Group LLC now owns 1,537 shares of the medical equipment provider’s stock valued at $316,000 after purchasing an additional 61 shares during the period. Institutional investors and hedge funds own 94.69% of the company’s stock.

Insider Buying and Selling

In other news, SVP Cary L. Majors sold 1,682 shares of STERIS stock in a transaction on Monday, November 25th. The shares were sold at an average price of $217.32, for a total value of $365,532.24. Following the transaction, the senior vice president now directly owns 11,372 shares of the company’s stock, valued at $2,471,363.04. The trade was a 12.88 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. 1.14% of the stock is currently owned by company insiders.

STERIS Stock Up 0.1 %

STE stock opened at $219.54 on Tuesday. The stock has a market cap of $21.67 billion, a P/E ratio of 46.61 and a beta of 0.84. The company has a current ratio of 2.13, a quick ratio of 1.55 and a debt-to-equity ratio of 0.32. STERIS plc has a twelve month low of $197.82 and a twelve month high of $248.24. The company’s 50 day moving average is $213.03 and its two-hundred day moving average is $223.83.

STERIS (NYSE:STEGet Free Report) last announced its quarterly earnings results on Wednesday, February 5th. The medical equipment provider reported $2.32 EPS for the quarter, missing the consensus estimate of $2.33 by ($0.01). STERIS had a return on equity of 13.91% and a net margin of 8.66%. Research analysts expect that STERIS plc will post 9.08 earnings per share for the current fiscal year.

STERIS Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Friday, March 21st. Investors of record on Thursday, February 20th will be given a $0.57 dividend. The ex-dividend date of this dividend is Thursday, February 20th. This represents a $2.28 dividend on an annualized basis and a dividend yield of 1.04%. STERIS’s dividend payout ratio (DPR) is presently 48.41%.

Wall Street Analyst Weigh In

A number of equities research analysts have issued reports on the company. JMP Securities reaffirmed a “market outperform” rating and issued a $265.00 price target on shares of STERIS in a research report on Thursday, February 6th. Stephens reiterated an “overweight” rating and issued a $240.00 price target on shares of STERIS in a research note on Thursday, February 6th. Piper Sandler increased their price objective on shares of STERIS from $260.00 to $265.00 and gave the company an “overweight” rating in a research report on Monday, February 3rd. Needham & Company LLC restated a “hold” rating on shares of STERIS in a report on Friday, November 8th. Finally, StockNews.com downgraded shares of STERIS from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, October 29th. One equities research analyst has rated the stock with a hold rating and five have given a buy rating to the company. According to data from MarketBeat, STERIS has a consensus rating of “Moderate Buy” and an average price target of $258.75.

Check Out Our Latest Stock Analysis on STERIS

STERIS Profile

(Free Report)

STERIS plc provides infection prevention products and services worldwide. It operates through four segments: Healthcare, Applied Sterilization Technologies, Life Sciences, and Dental. The Healthcare segment offers cleaning chemistries and sterility assurance products; automated endoscope reprocessing system and tracking products; endoscopy accessories, washers, sterilizers, and other pieces of capital equipment for the operation of a sterile processing department; and equipment used directly in the operating room, including surgical tables, lights, and connectivity solutions, as well as equipment management services.

Further Reading

Want to see what other hedge funds are holding STE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for STERIS plc (NYSE:STEFree Report).

Institutional Ownership by Quarter for STERIS (NYSE:STE)

Receive News & Ratings for STERIS Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for STERIS and related companies with MarketBeat.com's FREE daily email newsletter.